TrialResults-center.org

Menu

Description Results

Group by...

in first

in second

in third

All pathologies
coronary artery disease
stable angina

all indication together 18 - 1
all type of patient 25 - 1
all type of patient 26 - 1
all type of patients 206 - 79
unparticular patients 215 - 79

pdf

pathology

Benefit (demonstrated or suggested) and harm

coronary artery disease

All results are NS for efficacy

Trial

control

p<0.05

harm

NS

ACTION, 2004

vs bare-metal stent

angioplastie 0.06 [0.03; 0.11]

MACE 0.07 [0.04; 0.11]

CABG 0.09 [0.01; 0.74]

all cause mortality 0.44 [0.03; 6.89]

MI 2.61 [0.32; 21.42]

target lesion revascularisation (TLR ) 0.26 [0.06; 1.07]

Trial

Treatments

Patients

Method

ACTION, 2004

Multilink Tetra stent (n=241)

vs.

uncoated Multilink Tetra stent (n=119)

Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent

single-blind

Parallel groups

Sample size: 241/119

Primary endpoint: major adverse cardiac events at 30d

FU duration: 6 months

stable angina

All results are NS for efficacy

Trial

control

p<0.05

harm

NS

ACTION, 2004

vs bare-metal stent

angioplastie 0.06 [0.03; 0.11]

MACE 0.07 [0.04; 0.11]

CABG 0.09 [0.01; 0.74]

all cause mortality 0.44 [0.03; 6.89]

MI 2.61 [0.32; 21.42]

target lesion revascularisation (TLR ) 0.26 [0.06; 1.07]

Trial

Treatments

Patients

Method

ACTION, 2004

Multilink Tetra stent (n=241)

vs.

uncoated Multilink Tetra stent (n=119)

Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent

single-blind

Parallel groups

Sample size: 241/119

Primary endpoint: major adverse cardiac events at 30d

FU duration: 6 months

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -